DRUG Stock Overview
A biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bright Minds Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$52.31 |
| 52 Week High | CA$108.00 |
| 52 Week Low | CA$1.29 |
| Beta | 1.13 |
| 11 Month Change | -22.50% |
| 3 Month Change | 3,410.74% |
| 1 Year Change | 2,977.06% |
| 33 Year Change | 91.26% |
| 5 Year Change | n/a |
| Change since IPO | 25.29% |
Recent News & Updates
Recent updates
Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth
Oct 16
Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely
Aug 19We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully
Mar 07We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely
Nov 04Shareholder Returns
| DRUG | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -11.3% | -6.8% | 0.4% |
| 1Y | 2,977.1% | -0.4% | 21.4% |
Return vs Industry: DRUG exceeded the Canadian Biotechs industry which returned -0.4% over the past year.
Return vs Market: DRUG exceeded the Canadian Market which returned 21.4% over the past year.
Price Volatility
| DRUG volatility | |
|---|---|
| DRUG Average Weekly Movement | 995.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: DRUG's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine DRUG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Ian McDonald | brightmindsbio.com |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety.
Bright Minds Biosciences Inc. Fundamentals Summary
| DRUG fundamental statistics | |
|---|---|
| Market cap | CA$364.84m |
| Earnings (TTM) | -CA$3.58m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-101.9x
P/E RatioIs DRUG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRUG income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.58m |
| Earnings | -CA$3.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DRUG perform over the long term?
See historical performance and comparison